Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Mult Scler
; 21(4): 481-4, 2015 Apr.
Article
em En
| MEDLINE
| ID: mdl-25078275
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab treatment. Restoring immune function by plasmapheresis/immunoadsorption (PLEX/IA) is important for the outcome of PML. We report on four multiple sclerosis (MS) patients whom developed PML during natalizumab treatment, in whom we measured serum natalizumab concentrations before and during PLEX. Depending on the serum natalizumab concentration at the time of PML diagnosis, the number of PLEX treatments necessary to reach subtherapeutic serum natalizumab concentrations is variable. Measuring serum natalizumab concentrations before and during PLEX is helpful to determine the optimum number of PLEX treatments in individual MS patients with PML.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucoencefalopatia Multifocal Progressiva
/
Esclerose Múltipla Recidivante-Remitente
/
Natalizumab
/
Fatores Imunológicos
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Mult Scler
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Holanda